Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00312026 |
This is a Phase IV randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SC efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque psoriasis involving the hands and/or feet who have had no previous exposure to efalizumab. The study will consist of a screening period, a treatment period, and an observation period.
Condition | Intervention | Phase |
---|---|---|
Psoriasis |
Drug: efalizumab |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet |
Estimated Enrollment: | 75 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | November 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | ACD3753g |
Study First Received: | April 5, 2006 |
Last Updated: | July 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00312026 |
Health Authority: | United States: Institutional Review Board |
Plaque Psoriasis Hands Feet Hand |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |